Tag Archive for: Wegovy

Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply, according to an analysis of U.S. pharmacy claims shared with Reuters.

Novo Nordisk will start selling its hugely popular obesity drug Wegovy in Germany this month, its third European market, but only people who pay from their own pocket or have certain private health insurance plans will be able to get it.

Novo Nordisk is the only company with FDA approval to sell semaglutide drugs. It said that the pharmacies are selling new drugs without FDA approval and claiming to compete with Novo Nordisk’s approved drugs, violating federal and state law.

People taking popular diabetes and weight loss drugs such as Novo Nordisk’s Ozempic and Wegovy or Eli Lilly’s Mounjaro should temporarily stop taking them before having elective surgery to avoid possible serious complications, the American Society of Anesthesiologists (ASA) said on Thursday.

While many employers have been covering weight-loss drugs, Wegovy’s high price and the huge increase in people taking it has them reconsidering when and how to reimburse use of such treatments to prevent a steep spike in health insurance costs, three healthcare industry experts say.

Novo plans to seek U.S. and European regulatory approval of the high-dose pill later this year, but timing of a market launch is “to be determined,” according to Mico Guevarra, medical director at Novo Nordisk.

A thyroid cancer safety signal was raised by the EU’s drugs watchdog last month over several Novo Nordisk (NOVOb.CO) products including semaglutide, which is used in popular diabetes and obesity medicines Ozempic and Wegovy.

Wegovy maker Novo Nordisk on Tuesday said it had sued some medical spas and wellness clinics in the United States for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss and diabetes drugs.

Novo Nordisk’s launch of obesity drug Wegovy in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, executives said on Tuesday, as demand booms in the United States.

Britain will launch a pilot program to explore how new weekly weight-loss shots such as Novo Nordisk’s Wegovy can be given to obese patients outside of limited specialist services even as the drug’s market launch remains unclear.